<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease (BD) is a multisystem <z:hpo ids='HP_0002633'>vasculitis</z:hpo> of unknown origin </plain></SENT>
<SENT sid="1" pm="."><plain>Visual outcome in BD is bad irrespective of therapy </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated in a prospective, open clinical trial wether interferon alpha2a (IFN alpha2a) is effective as single agent in severe ocular BD </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: 33 patients (11 female, 22 male) with severe ocular BD (<z:hpo ids='HP_0012123'>posterior uveitis</z:hpo>/<z:hpo ids='HP_0012121'>panuveitis</z:hpo>), fulfilling the Criteria of the "International Study Group of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's Disease", were treated with IFN alpha2a </plain></SENT>
<SENT sid="4" pm="."><plain>Other immunosuppressive drugs were stopped at the beginning of interferon-therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Efficacy was evaluated by the <z:hpo ids='HP_0000554'>uveitis</z:hpo> scoring system (Ben Ezra et al.), visual acuity and BD activity score (Rigby et al.) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In 32 (97 %) patients complete remission of the inflammatory changes occured </plain></SENT>
<SENT sid="7" pm="."><plain>Mean <z:hpo ids='HP_0012123'>posterior uveitis</z:hpo> score fell from 3.7 to 0.4, visual acuity rose from 0.5 to 0.9, and mean BD activity score fell from 5.1 to 3.0 during a mean observation period of 28.6 months </plain></SENT>
<SENT sid="8" pm="."><plain>There was only one non-responder </plain></SENT>
<SENT sid="9" pm="."><plain>Side effects were <z:hpo ids='HP_0001596'>hair loss</z:hpo> (69 %), <z:hpo ids='HP_0000716'>depression</z:hpo> (36 %), <z:e sem="disease" ids="C0033774" disease_type="Disease or Syndrome" abbrv="">itching</z:e> (33 %), <z:e sem="disease" ids="C0016053" disease_type="Disease or Syndrome" abbrv="">fibromyalgia</z:e> (10 %), and the development of autoantibodies (21 %) </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0001945'>Fever</z:hpo>, <z:hpo ids='HP_0002829'>arthralgia</z:hpo> and <z:hpo ids='HP_0002315'>headache</z:hpo> occured in <z:hpo ids='HP_0000001'>all</z:hpo> patients, but only during the first weeks of therapy </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: IFN alpha2a seems to be very effective in ocular BD </plain></SENT>
<SENT sid="12" pm="."><plain>Controlled randomized studies are warranted in order to prove the efficacy of IFN alpha2a in ocular BD and to compare it with other, established treatments, such as <z:chebi fb="2" ids="2948">azathioprine</z:chebi> or <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> </plain></SENT>
</text></document>